Literature DB >> 22424219

Antibody-based immunotherapy of cancer.

Louis M Weiner1, Joseph C Murray, Casey W Shuptrine.   

Abstract

By targeting surface antigens expressed on tumor cells, monoclonal antibodies have demonstrated efficacy as cancer therapeutics. Recent successful antibody-based strategies have focused on enhancing antitumor immune responses by targeting immune cells, irrespective of tumor antigens. We discuss these innovative strategies and propose how they will impact the future of antibody-based cancer therapy.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22424219      PMCID： PMC3310896          DOI： 10.1016/j.cell.2012.02.034

Source DB:  PubMed          Journal:  Cell        ISSN： 0092-8674            Impact factor:   41.582


  20 in total

1.  Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

Authors:  Caroline Robert; Luc Thomas; Igor Bondarenko; Steven O'Day; Jeffrey Weber; Claus Garbe; Celeste Lebbe; Jean-François Baurain; Alessandro Testori; Jean-Jacques Grob; Neville Davidson; Jon Richards; Michele Maio; Axel Hauschild; Wilson H Miller; Pere Gascon; Michal Lotem; Kaan Harmankaya; Ramy Ibrahim; Stephen Francis; Tai-Tsang Chen; Rachel Humphrey; Axel Hoos; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2011-06-05       Impact factor: 91.245

Review 2.  Antibody-radionuclide conjugates for cancer therapy: historical considerations and new trends.

Authors:  Martina Steiner; Dario Neri
Journal:  Clin Cancer Res       Date:  2011-10-15       Impact factor: 12.531

3.  A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies.

Authors:  Gabriele Schaefer; Lauric Haber; Lisa M Crocker; Steven Shia; Lily Shao; Donald Dowbenko; Klara Totpal; Anne Wong; Chingwei V Lee; Scott Stawicki; Robyn Clark; Carter Fields; Gail D Lewis Phillips; Rodney A Prell; Dimitry M Danilenko; Yvonne Franke; Jean-Philippe Stephan; Jiyoung Hwang; Yan Wu; Jenny Bostrom; Mark X Sliwkowski; Germaine Fuh; Charles Eigenbrot
Journal:  Cancer Cell       Date:  2011-10-18       Impact factor: 31.743

4.  Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.

Authors:  R A Clynes; T L Towers; L G Presta; J V Ravetch
Journal:  Nat Med       Date:  2000-04       Impact factor: 53.440

5.  Targeting intracellular oncoproteins with antibody therapy or vaccination.

Authors:  Ke Guo; Jie Li; Jing Ping Tang; Cheng Peow Bobby Tan; Cheng William Hong; Abdul Qader O Al-Aidaroos; Leyon Varghese; Caixia Huang; Qi Zeng
Journal:  Sci Transl Med       Date:  2011-09-07       Impact factor: 17.956

6.  Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody.

Authors:  P Ruf; H Lindhofer
Journal:  Blood       Date:  2001-10-15       Impact factor: 22.113

Review 7.  The role of TNF superfamily members in T-cell function and diseases.

Authors:  Michael Croft
Journal:  Nat Rev Immunol       Date:  2009-04       Impact factor: 53.106

Review 8.  Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.

Authors:  Robert D Schreiber; Lloyd J Old; Mark J Smyth
Journal:  Science       Date:  2011-03-25       Impact factor: 47.728

9.  Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells.

Authors:  B Sauter; M L Albert; L Francisco; M Larsson; S Somersan; N Bhardwaj
Journal:  J Exp Med       Date:  2000-02-07       Impact factor: 14.307

10.  Antitumor monoclonal antibodies enhance cross-presentation ofcCellular antigens and the generation of myeloma-specific killer T cells by dendritic cells.

Authors:  Kavita M Dhodapkar; Joseph Krasovsky; Barbara Williamson; Madhav V Dhodapkar
Journal:  J Exp Med       Date:  2002-01-07       Impact factor: 14.307
View more
  80 in total

1.  Efficient method to optimize antibodies using avian leukosis virus display and eukaryotic cells.

Authors:  Changming Yu; Gennett M Pike; Tommy A Rinkoski; Cristina Correia; Scott H Kaufmann; Mark J Federspiel
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-27       Impact factor: 11.205

Review 2.  A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy.

Authors:  Pravin T P Kaumaya
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Antibody Distance from the Cell Membrane Regulates Antibody Effector Mechanisms.

Authors:  Kirstie L S Cleary; H T Claude Chan; Sonja James; Martin J Glennie; Mark S Cragg
Journal:  J Immunol       Date:  2017-04-12       Impact factor: 5.422

4.  Identification and grafting of a unique peptide-binding site in the Fab framework of monoclonal antibodies.

Authors:  Joshua M Donaldson; Cindy Zer; Kendra N Avery; Krzysztof P Bzymek; David A Horne; John C Williams
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-07       Impact factor: 11.205

Review 5.  Considerations for the Design of Antibody-Based Therapeutics.

Authors:  Dennis R Goulet; William M Atkins
Journal:  J Pharm Sci       Date:  2019-06-04       Impact factor: 3.534

Review 6.  Cancer nanomedicines: so many papers and so few drugs!

Authors:  Vincent J Venditto; Francis C Szoka
Journal:  Adv Drug Deliv Rev       Date:  2012-10-01       Impact factor: 15.470

7.  Macrophages eliminate circulating tumor cells after monoclonal antibody therapy.

Authors:  Nuray Gül; Liane Babes; Kerstin Siegmund; Rianne Korthouwer; Marijn Bögels; Rens Braster; Gestur Vidarsson; Timo L M ten Hagen; Paul Kubes; Marjolein van Egmond
Journal:  J Clin Invest       Date:  2014-01-16       Impact factor: 14.808

8.  PRL3-zumab, a first-in-class humanized antibody for cancer therapy.

Authors:  Min Thura; Abdul Qader Omer Al-Aidaroos; Wei Peng Yong; Koji Kono; Abhishek Gupta; You Bin Lin; Kousaku Mimura; Jean Paul Thiery; Boon Cher Goh; Patrick Tan; Ross Soo; Cheng William Hong; Lingzhi Wang; Suling Joyce Lin; Elya Chen; Sun Young Rha; Hyun Cheol Chung; Jie Li; Sayantani Nandi; Hiu Fung Yuen; Shu-Dong Zhang; Yeoh Khay Guan; Jimmy So; Qi Zeng
Journal:  JCI Insight       Date:  2016-06-16

Review 9.  Mechanisms of action of therapeutic antibodies for cancer.

Authors:  J M Redman; E M Hill; D AlDeghaither; L M Weiner
Journal:  Mol Immunol       Date:  2015-04-23       Impact factor: 4.407

10.  Anti-Jagged Immunotherapy Inhibits MDSCs and Overcomes Tumor-Induced Tolerance.

Authors:  Rosa A Sierra; Jimena Trillo-Tinoco; Eslam Mohamed; Lolie Yu; Bhagelu R Achyut; Ali Arbab; Jennifer W Bradford; Barbara A Osborne; Lucio Miele; Paulo C Rodriguez
Journal:  Cancer Res       Date:  2017-09-13       Impact factor: 12.701
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.